Loading...
ALXP
ALTHE
Market cap56mUSD
Oct 28, Last price  
0.69EUR
1D
6.00%
1Q
15.99%
Jan 2017
-86.83%
IPO
-94.78%
Name

Theraclion SA

Chart & performance

D1W1MN
ALXP:ALTHE chart
P/E
—
P/S
42.90
EPS
—
Vol. 1Y
82.11%
Shs. 5Y
29.88%
Rev. 5Y
9.77%
Div Yld LY
—
Div Yld TTM
—
Revenues
1m
+42.84%
212,960937,420376,497819,6771,530,9221,975,0202,824,2981,928,8242,784,000744,0001,481,0001,235,4521,822,221830,0001,185,555
Net income
-6m
L-1.20%
-1,914,995-1,675,036-3,072,756-4,110,809-4,634,060-6,412,745-6,535,938-6,224,063-6,144,459-3,792,000-3,905,000-3,760,000-4,964,383-3,675,005-5,757,000-5,687,868
CFO
-7m
L+145.93%
-952,018-2,659,813-4,037,826-5,177,675-4,978,661-7,965,194-6,785,169-4,730,847-3,693,187-3,322,892-3,883,766-5,266,024-2,484,741-2,911,000-7,159,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.

Key people

Yann Duchesne
Chairman of the Board · since 2022
Martin Deterre
Chief Executive Officer · since 2023
Lijuan Deng
Director · since 2023
Xin Lin
Director · since 2023
Cedric Bellanger
Independent Director · since 2022
Mehdi El Glaoui
Independent Director · since 2021
Ari Kellen
Independent Director · since 2020
Shawn Langer
Independent Director · since 2019
Claude Lenoir
Independent Director · since 2023
URL
https://www.theraclion.fr/
IPO date
Apr 25, 2014
Employees
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
240 AVENUE PIERRE BROSSOLETTE
LE VAILLANT
MALAKOFF 92240
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT